Novavax (NASDAQ:NVAX) Shares Gap Down – Should You Sell?

Novavax, Inc. (NASDAQ:NVAX) shares gapped down before the market opened on Monday . The stock had previously closed at $7.00, but opened at $6.49. Novavax shares last traded at $6.56, with a volume of 1,039,722 shares.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on NVAX shares. HC Wainwright reiterated a “buy” rating and set a $19.00 price objective on shares of Novavax in a report on Tuesday, December 10th. BTIG Research assumed coverage on shares of Novavax in a research report on Friday, February 28th. They issued a “buy” rating and a $19.00 price target on the stock. Finally, TD Cowen raised Novavax to a “hold” rating in a report on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $18.00.

Novavax Price Performance

The firm’s fifty day moving average is $8.13 and its two-hundred day moving average is $9.32. The firm has a market capitalization of $1.05 billion, a PE ratio of -2.86, a PEG ratio of 2.85 and a beta of 2.92.

Novavax (NASDAQ:NVAX) last announced its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.24. The business had revenue of $88.31 million during the quarter, compared to analysts’ expectations of $85.48 million. During the same quarter in the previous year, the firm earned ($1.44) EPS. As a group, equities research analysts predict that Novavax, Inc. will post -1.46 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director James F. Young sold 5,400 shares of Novavax stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $8.00, for a total transaction of $43,200.00. Following the sale, the director now directly owns 51,760 shares in the company, valued at $414,080. The trade was a 9.45 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 1.00% of the company’s stock.

Institutional Trading of Novavax

Hedge funds have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. bought a new position in shares of Novavax during the 4th quarter valued at approximately $27,000. Spire Wealth Management bought a new position in Novavax during the fourth quarter valued at $29,000. New Age Alpha Advisors LLC purchased a new stake in Novavax in the fourth quarter worth $35,000. KBC Group NV raised its stake in shares of Novavax by 97.0% in the fourth quarter. KBC Group NV now owns 7,954 shares of the biopharmaceutical company’s stock valued at $64,000 after buying an additional 3,917 shares during the period. Finally, TigerOak Management L.L.C. purchased a new position in shares of Novavax during the 4th quarter valued at $86,000. Institutional investors own 53.04% of the company’s stock.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.